Citius Oncology Highlighted Phase 1 Clinical Data Presented May 30, 2026, At The American Society Of Clinical Oncology Annual Meeting Evaluating Lymphir (Denileukin Diftitox-cxdl) In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies

Loading news article.

Citius Oncology Highlighted Phase 1 Clinical Data Presented May 30, 2026, At The American Society Of Clinical Oncology Annual Meeting Evaluating Lymphir (Denileukin Diftitox-cxdl) In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies | WAPE

Citius Oncology Highlighted Phase 1 Clinical Data Presented May 30, 2026, At The American Society Of Clinical Oncology Annual Meeting Evaluating Lymphir (Denileukin Diftitox-cxdl) In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies

Article summary

Related companies

Comments —